Generation Bio Co. GBIO · Stock Open Generation Bio Co. in new tab
Generation Bio Co. Analysis (GBIO)
Is Generation Bio Co. a good investment? Generation Bio Co. (GBIO) is currently trading at 5.34 USD. Market analysts have a consensus price target of 5.25 USD. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Generation Bio Co. is expected to release its next earnings report on March 12, 2026. The market consensus estimate for Forward EPS is -1.34.
Investor FAQ
Does Generation Bio Co. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Generation Bio Co.?
Generation Bio Co. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be March 12, 2026. The company currently has a trailing EPS of -9.37.
Company Profile
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| July 22, 2025 | 1:10 |
Community Discussion